Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The companys lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York City, New York, the US.

Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Akebia Therapeutics and Keryx Biopharma to Merge 11
Equity Offering 13
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 13
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 16
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 18
Debt Offering 20
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Acquisition 21
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc - Key Competitors 22
Keryx Biopharmaceuticals Inc - Key Employees 23
Keryx Biopharmaceuticals Inc - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
May 10, 2018: Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results 25
Feb 07, 2018: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 27
Nov 07, 2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results 29
Jul 27, 2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance 30
May 04, 2017: Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results 32
Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 34
Corporate Communications 36
Apr 30, 2018: Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue 36
Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akebia Therapeutics and Keryx Biopharma to Merge 11
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 13
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 16
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 18
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc, Key Competitors 22
Keryx Biopharmaceuticals Inc, Key Employees 23
Keryx Biopharmaceuticals Inc, Subsidiaries 24

List Of Figures

List of Figures
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The companys lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate

USD 250 View Report

Keryx Biopharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Keryx Biopharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Keryx Biopharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review

Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Sienna Biopharmaceuticals Inc (SNNA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a clinical-stage biopharmaceutical company that develops innovation therapies for inflammatory skin and aesthetic conditions. It offers topical by design or low systemic exposure technology

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available